Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.
IPO Year: 1990
Exchange: NASDAQ
Website: hologic.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | Peer Perform | Wolfe Research | |
| 12/10/2024 | $90.00 | Buy | Needham |
| 12/10/2024 | $85.00 | Hold | Jefferies |
| 10/1/2024 | $95.00 → $85.00 | Buy → Neutral | Citigroup |
| 6/27/2024 | $87.00 | Overweight | Stephens |
| 4/3/2024 | $80.00 → $95.00 | Neutral → Buy | Citigroup |
| 7/14/2023 | $95.00 | Hold → Buy | Needham |
| 12/7/2022 | $75.00 | Sector Perform | RBC Capital Mkts |
| 10/13/2022 | $75.00 | Buy | Mizuho |
| 7/20/2022 | $73.00 | Neutral | UBS |
DEFA14A - HOLOGIC INC (0000859737) (Filer)
DEF 14A - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
10-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
8-K - HOLOGIC INC (0000859737) (Filer)
144 - HOLOGIC INC (0000859737) (Subject)
– Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance – – GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges – Hologic, Inc. (NASDAQ:HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2024. The Company expects to report total revenues of approximately $1,021.8 million, an increase of 0.9% compared to the prior year period, or 1.0% in constant currency. "Our fiscal Q1 revenue finished in line with our guidance on a constant currency basis, as the strengthening of the U.S. dollar reduced revenue by approximately $9 million compared to when we provided g
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic's website at http://investors.hologic.com. The webcast will be available for 30 days following the event. About Hologic, Inc. Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4103504. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.ho
Hologic, Inc. (NASDAQ:HOLX), a global leader in women's health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women's health, for approximately $350 million. "We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata® System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids," said Brandon Schnittker, President of Surgical Solutions at Hologic. "As global champions for women's health, we are dedicated to empowering surgeons with diverse, cutting-edge treatmen
Hologic, Inc. (NASDAQ:HOLX) today announced that it has entered into an agreement with the Centers for Disease Control and Prevention (CDC) to develop analyte specific reagents (ASRs) — the "active ingredients" of laboratory-developed tests used to identify specific diseases or conditions — that would aid in the detection of H5N1 bird flu. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218942183/en/Panther Fusion® system (Photo: Business Wire) H5N1 bird flu, also known as avian influenza A (H5N1), continues to spread among wild birds worldwide and is causing outbreaks in poultry and dairy cows in the U.S., with several recent
Hologic, Inc., (NASDAQ:HOLX) a global leader in women's health focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions, today issued the following statement regarding the United States Preventive Services Task Force draft guidelines for cervical cancer screening: "Today's recommendations are an important acknowledgement of the role of Pap testing combined with HPV testing, which is the gold standard of care and the most effective method of identifying cervical cancer," said Jennifer Schneiders, PhD, President, Diagnostic Solutions at Hologic. "Eliminating cervical cancer is within our reach and history has shown us that safeguard
Hologic, Inc. (NASDAQ:HOLX) announced today that Martin Madaus has been elected to the Company's Board of Directors, effective December 6, 2024. Dr. Madaus was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209400549/en/Dr. Martin Madaus (Photo: Business Wire) Dr. Madaus, who has more than 30 years of diagnostics and life sciences industry experience, currently serves as an Operating Executive at the Carlyle Group, a global investment firm, which he joined in February 2019. Prior to joining the Carlyl
Study Assesses Prognostic Value of BCI Testing and Its Potential in Supporting De-escalation of Primary Adjuvant Endocrine Therapy Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among these studies, initial data will be premiered investigating the potential role of the BCI test to identify postmenopausal women with hormone-receptor positive (HR+), early-stage, node-negative disease who are at minimal risk of experiencing a distant recurrence. Full results will be shared during Poster Session 1 on December 11, 2024, at 12:30 p.m. CT [#P1-09-13]. "Given challenges with tolerability of primary adjuvan
Leader in Women's Health Unveils Data Underscoring Its Commitment to Reducing Bias in Breast Cancer Detection Hologic, Inc. (NASDAQ:HOLX) yesterday presented new research demonstrating the performance of its Genius AI® Detection 2.0 software across diverse patient populations at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241202326112/en/GAI 2.0 (Graphic: Business Wire) Artificial intelligence (AI) is increasingly used to aid in the diagnosis of breast cancer, as well as in predicting a patient's risk level and breast densi
Leader in Women's Health Will Unveil Groundbreaking Innovations With a Focus on Imaging Solutions and Artificial Intelligence Hologic, Inc. (NASDAQ:HOLX) will reveal new technologies reimagining the future of breast health at the 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago on December 1-5. On the show floor and during multiple workshops, Hologic will showcase AI-powered breast imaging advancements designed to assess breast density, enhance workflows and improve cancer detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241125586668/en/Experience the cutting-
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
3 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
4 - HOLOGIC INC (0000859737) (Issuer)
Wolfe Research initiated coverage of Hologic with a rating of Peer Perform
Needham reiterated coverage of Hologic with a rating of Buy and set a new price target of $90.00
Jefferies initiated coverage of Hologic with a rating of Hold and set a new price target of $85.00
Citigroup downgraded Hologic from Buy to Neutral and set a new price target of $85.00 from $95.00 previously
Stephens initiated coverage of Hologic with a rating of Overweight and set a new price target of $87.00
Citigroup upgraded Hologic from Neutral to Buy and set a new price target of $95.00 from $80.00 previously
Needham upgraded Hologic from Hold to Buy and set a new price target of $95.00
RBC Capital Mkts initiated coverage of Hologic with a rating of Sector Perform and set a new price target of $75.00
Mizuho initiated coverage of Hologic with a rating of Buy and set a new price target of $75.00
UBS initiated coverage of Hologic with a rating of Neutral and set a new price target of $73.00
Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t
MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders. "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics. "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo
BERWYN, Pa., Feb. 11, 2021 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that its Board of Directors has appointed Karleen Oberton as a new director of the Company. Ms. Oberton serves as Chief Financial Officer of Hologic, Inc. (NASDAQ: HOLX), an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment systems. "We are pleased to welcome Karleen to AMETEK as a member of our Board of Directors," commented David A. Zapico, AMETEK Chairman and Chief Executive Officer. "Karleen is a skilled business executive with more than 30 years of experience in public accounting, biotechnology and medical device m
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020. The Company expects to report total revenues of approximately $1,609.8 million, an increase of 89.3% compared to the prior year period, or 86.5% in constant currency. These preliminary results compare to the Company’s most recent guidance range of $1,350 to $1,425 million, which was provided on November 4, 2020. “Hologic’s strong momentum continued in the first quarter of fiscal 2021 as organic revenue more than doubled, well ahead of our prior expectations,” said Steve MacMillan, the Company’s Chairman, President and
For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod
For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2025 on Wednesday, February 5, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4103504. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.ho
– Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 28, 2024. "We delivered strong fiscal 2024 results, reinforcing our track record of durable performance with another solid quarter of growth," said Steve MacMillan, Hologic's chairman, president, and chief executive officer. "Each year we grow stronger, leveraging our
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2024 on Monday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 4567924. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.ho
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Year Period – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 29, 2024. "In our third quarter of fiscal 2024, Hologic returns to top-line reported growth and once again exceeded the high-end of our guidance for both the top and bottom-line," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Our strong fiscal qua
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2024 on Monday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5372869. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.holo
– Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 30, 2024. "At Hologic we continue to deliver, exceeding the high-end of our guidance for both the top and bottom-line, highlighting our durable growth even as we faced incredibly high
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 256-1007 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 7680382. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at www.investors.hol
– Revenue of $1,013.1 Million, GAAP Diluted EPS of $1.03, and Non-GAAP Diluted EPS of $0.98; All Exceed Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 5.2% in Constant Currency Against Four Fewer Selling Days Compared to the Prior Year Period – – Company Increases Full-Year Revenue and EPS Guidance - Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 30, 2023. "We delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line. Adjusting for the four fewer selling days in the quarter, we estimate our organic g
Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 394-8218 (in the United States and Canada) or +1 (773) 305-6853 (for international callers) and referencing access code 5909239. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at https://inves
– Revenue of $945.3 Million, GAAP Diluted EPS of $0.37, and Non-GAAP Diluted EPS of $0.89 – – Total Company Organic Revenue Growth excluding COVID-19 of 16.7% in constant currency – – Expect Broad Based Strong Performance in Fiscal 2024 – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 30, 2023. "Hologic delivered remarkable fiscal 2023 results extending our track record of strong performance with another solid quarter of growth in our fourth quarter," said Steve MacMillan, the Company's chairman, president and chief executive officer. "Each one of our divisions grew double digits organically in the quarter an
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)
SC 13G/A - HOLOGIC INC (0000859737) (Subject)